Cargando…
Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study
BACKGROUND: The FLAME study compared once-daily indacaterol/glycopyrronium (IND/GLY) 110/50 μg with twice-daily salmeterol/fluticasone (SFC) 50/500 μg in symptomatic patients with moderate to very severe COPD and a history of exacerbations in the previous year. METHODS: This prespecified and post ho...
Autores principales: | Vogelmeier, Claus F, Chapman, Kenneth R, Miravitlles, Marc, Roche, Nicolas, Vestbo, Jørgen, Thach, Chau, Banerji, Donald, Fogel, Robert, Patalano, Francesco, Olsson, Petter, Kostikas, Konstantinos, Wedzicha, Jadwiga A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901128/ https://www.ncbi.nlm.nih.gov/pubmed/29692607 http://dx.doi.org/10.2147/COPD.S160011 |
Ejemplares similares
-
Impact of baseline symptoms and health status on COPD exacerbations in the FLAME study
por: Mackay, Alexander J., et al.
Publicado: (2020) -
Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study
por: Wedzicha, Jadwiga A, et al.
Publicado: (2017) -
Early Clinically Important Improvement (ECII) and Exacerbation Outcomes in COPD Patients
por: Kostikas, Konstantinos, et al.
Publicado: (2020) -
Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study
por: Anzueto, Antonio R., et al.
Publicado: (2018) -
Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population
por: Vestbo, Jørgen, et al.
Publicado: (2019)